FDA Releases Tips for Animal Studies in Bone Grafting Devices
Published Date: 8/22/2025
Notice
Summary
The FDA just released clear advice for companies making dental bone grafting materials on how to do animal studies for their 510(k) submissions. This helps speed up reviews and makes sure everyone follows the same rules. If you’re in this business, get ready to save time and avoid costly mistakes!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Guidance for Dental Graft Devices
If you make dental bone grafting material devices, the FDA released final guidance on recommended animal study designs and the animal-study information to include in a Premarket Notification (510(k)) submission. The guidance may help manufacturers comply with some special controls and is intended to promote consistency and facilitate efficient review of those 510(k) submissions.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12445 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Traction Device
The FDA is officially putting the endoscopic traction device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get access to this cool medical tool. The new rules took effect on June 22, 2026, and could speed up innovation without extra costs for makers.
2026-12444 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
The FDA is officially putting the endoscopic light-projecting measuring device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to cool new tech. The new rules took effect June 22, 2026, and could save time and money for makers and users alike.
2026-12367 — Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
Epizyme, Inc. has asked the FDA to withdraw approval for their cancer drug TAZVERIK (200 mg tablets), effective June 22, 2026. This means TAZVERIK will no longer be officially approved for treating certain sarcomas and lymphomas, affecting patients and healthcare providers relying on it. The change might impact treatment options and insurance coverage, so folks should check with their doctors about next steps.
2026-12443 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple In Vitro Diagnostic Device for the Detection of Secreted Proteins From Bacillus Species (spp.) in Human Clinical Samples
The FDA is officially putting a simple test that spots proteins from Bacillus bacteria in human samples into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while speeding up patient access to cool new medical tools. The new rules kicked in on June 22, 2026, but have been in effect since February 3, 2023, making life simpler for device makers and patients alike.
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2025-16136 — Request for Nominations of Members To Serve on the Healthcare Advisory Committee
The Department of Health and Human Services is looking for awesome people to join a new Healthcare Advisory Committee. If you care about health and want to help shape important decisions, now’s your chance to apply! This is a great opportunity to make a difference, with nominations open for a limited time and no cost to join.
Next: 2025-16138 — Yuba County Water Agency; Notice of Application for a Variance Under Article 33d Accepted for Filing, Soliciting Comments, Motions To Intervene, and Protests
The Yuba County Water Agency asked for a temporary change to how much water they release from their hydroelectric project on the Yuba River in California for 2026. This affects local rivers and nearby communities, and the public has until September 18, 2025, to share their thoughts or get involved. No big money changes are mentioned, but this tweak could impact river flow and the environment.